OptiBio

OptiBio is a South Korean in-vitro diagnostics (IVD) company focused in researching, developing, and manufacturing cutting edge fluorescence immunoassay (FIA) solutions. In 2020, OptiBio was selected by a research fund sponsored by the Bill & Melinda Gates foundation for its unique and dedicated approach to immunoassay. Our fundamental approach to in-house development allows OptiBio to constantly improve product performance, customize solutions based on client feedback, develop new test parameters, and respond to changing market needs. Shortly following the outbreak of Covid-19, for example, OptiBio quicky developed the Optical Q SARS-CoV-2 neutralizing antibody (nAb) test kit. OptiBio will continue to create, improve, and innovate world class diagnostic solutions in the field of fluorescence immunoassay and point-of-care testing (POCT). Through this, we aim to ultimately transform medical diagnosis into a universally available right.